Replies to post #247756 on Biotech Values

[DewDiligence]

Private company, CellTrans receives FDA approval for islet-cell therapy made from deceased-donors cells:

https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes

The therapy, called Lantidra, is infused into the liver’s portal vein. The recipient must take immunosuppressive drugs.

[DewDiligence]

VRTX discontinues VX-264 T1D treatment due to low efficacy; VX-880 remains and has been renamed, Zimislecel:

https://www.businesswire.com/news/home/20250328622122/en/Vertex-Announces-Program-Updates-for-Type-1-Diabetes-Portfolio

See #msg-172224254 for background info.